Cancer Treatment-Related Cardiotoxicity

Overview

Cancer treatment today employs a combination of chemotherapy, radiotherapy, immunotherapy, and surgery to prevent recurrence, prolong life and provide cure. However, many of these treatments can cause devastating cardiovascular complications for patients and survivors such as heart failure, myocardial ischemia/infarction, hypertension, thromboembolism, and arrhythmias. Developing and understanding optimal prevention, early detection and treatment strategies for cardiotoxicity related to anticancer treatment is a critical aspect of cancer patient care, and may have a significant impact on the overall prognosis and survival of cancer patients. These important clinical events are a significant challenge for both cardiologists and oncologists and will continue to be in the future, particularly due to an increasing aging population of patients with cancer and the introduction of many new targeted cancer therapies.

Efforts to identify individual toxicity risks and prevention strategies support the National Cancer Institute's (NCI) goal of reducing the burden of cancer diagnoses and treatment outcomes. NCI's vision for the future includes precision medicine that not only provides effective therapy for eradicating disease, but also maintains the function of normal tissues, thus decreasing the burden of cancer throughout the survivorship spectrum.

Funding Opportunities

NCI-sponsored notices of funding opportunities related to cancer treatment-related cardiotoxicity include:

• National Cancer Institute Program Project Applications for the Years 2023, 2024, and 2025 – expires May 8, 2026
  • PAR-23-059 (P01, Clinical Trial Optional)
• Cancer Prevention and Control Clinical Trials Grant Program – expires January 8, 2027
  • PAR-25-167 (R01, Clinical Trial Required)
• Cancer Prevention and Control Clinical Trials Planning Grant Program – expires October 26, 2027
  • PAR-25-104 (R34, Clinical Trials Optional)
• Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies – expires January 8, 2028
  • PAR-25-145 (R01, Clinical Trial Optional)

EGRP encourages investigator-initiated grant applications on this topic.

View other EGRP, NCI, and NIH funding opportunities

Workshops, Conferences, and Webinars

• Previous Events (sponsored by EGRP)
  • A Decade of NIH Cardio-Oncology Research Collaboration: Continued Funding Opportunities (December 2022)
  • Changing Hearts and Minds: Improving Outcomes in Cancer Treatment-Related Cardiotoxicity (June 2018)
  • State of the Science for Cancer Treatment-related Cardiotoxicities | Division of Cancer Prevention (July 2025)
• Previous Events (not sponsored by EGRP)
  • International CardiOncology Society (ICOS) (annual meetings)